Subscribe To
ROIV / Roivant Sciences earnings come in below Street estimates despite VTAMA sales growth
ROIV News
By Seeking Alpha
October 24, 2023
Roivant Sciences: Risk-Transforming Deal Met With Crickets
Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a more_horizontal
By Zacks Investment Research
September 27, 2023
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average. more_horizontal
By Proactive Investors
September 26, 2023
Roivant stock could go higher on monetization potential of ‘blockbuster' assets
Roivant shares finished more than 20% higher on Tuesday after Immunovant, in which Roivant holds a 56.5% stake, released positive data from an early-s more_horizontal
By Invezz
September 9, 2023
Roivant Sciences: Is this Vivek Ramaswamy's biotech stock a buy?
Roivant Sciences (NASDAQ: ROIV) stock price has entered a major bull run as investors remain optimistic about the company's future. The shares surged more_horizontal
By Seeking Alpha
August 14, 2023
Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Stephanie Lee - Vice President, more_horizontal
By Proactive Investors
August 14, 2023
Roivant Sciences earnings come in below Street estimates despite VTAMA sales growth
Roivant Sciences shares traded modestly higher after the inflammation and immunology-focused biopharmaceutical company reported fiscal first quarter f more_horizontal
By The Motley Fool
August 2, 2023
2 Magnificient Growth Stocks I'm Buying in August
Growth stocks have returned to form this year. Roivant Sciences and Viking Therapeutics are two growth plays that should interest risk-tolerant invest more_horizontal
By Zacks Investment Research
July 14, 2023
Roivant (ROIV) Up on Reports of Colitis Drug Sale to Roche
Shares of Roivant ROIV rose almost 12% on Thursday after a Wall Street Journal (WSJ) article reported that Roche RHHBY was close to buying ROIV's infl more_horizontal